| Style | Citing Format |
|---|---|
| MLA | M Noorafrooz MOHAMMADAMIN, et al.. "Betamethasone Dosing Intervals: The Overlooked Impact of Pharmacokinetic Variability." European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 312, no. , 2025, pp. -. |
| APA | M Noorafrooz MOHAMMADAMIN, S Abedinzadeh SHIVA, M Dashtkoohi MOHADESE, S Hantoushzadeh SEDIGHEH (2025). Betamethasone Dosing Intervals: The Overlooked Impact of Pharmacokinetic Variability. European Journal of Obstetrics and Gynecology and Reproductive Biology, 312(), -. |
| Chicago | M Noorafrooz MOHAMMADAMIN, S Abedinzadeh SHIVA, M Dashtkoohi MOHADESE, S Hantoushzadeh SEDIGHEH. "Betamethasone Dosing Intervals: The Overlooked Impact of Pharmacokinetic Variability." European Journal of Obstetrics and Gynecology and Reproductive Biology 312, no. (2025): -. |
| Harvard | M Noorafrooz MOHAMMADAMIN et al. (2025) 'Betamethasone Dosing Intervals: The Overlooked Impact of Pharmacokinetic Variability', European Journal of Obstetrics and Gynecology and Reproductive Biology, 312(), pp. -. |
| Vancouver | M Noorafrooz MOHAMMADAMIN, S Abedinzadeh SHIVA, M Dashtkoohi MOHADESE, S Hantoushzadeh SEDIGHEH. Betamethasone Dosing Intervals: The Overlooked Impact of Pharmacokinetic Variability. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2025;312():-. |
| BibTex | @article{ author = {M Noorafrooz MOHAMMADAMIN and S Abedinzadeh SHIVA and M Dashtkoohi MOHADESE and S Hantoushzadeh SEDIGHEH}, title = {Betamethasone Dosing Intervals: The Overlooked Impact of Pharmacokinetic Variability}, journal = {European Journal of Obstetrics and Gynecology and Reproductive Biology}, volume = {312}, number = {}, pages = {-}, year = {2025} } |
| RIS | TY - JOUR AU - M Noorafrooz MOHAMMADAMIN AU - S Abedinzadeh SHIVA AU - M Dashtkoohi MOHADESE AU - S Hantoushzadeh SEDIGHEH TI - Betamethasone Dosing Intervals: The Overlooked Impact of Pharmacokinetic Variability JO - European Journal of Obstetrics and Gynecology and Reproductive Biology VL - 312 IS - SP - EP - PY - 2025 ER - |